XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

				Three months ended September 30,								Nine months ended September 30,
Partner		Drug or Drug Candidate		2018				2017				2018				2017
Bristol-Myers Squibb		NKTR-214		$	—			$	—			$	1,059,768			$	—
Baxalta Incorporated/Shire		ADYNOVATE®			300				312				10,328				357
Eli Lilly and Company		NKTR-358			3,221				127,553				8,627				127,553
Amgen, Inc.		Neulasta®			1,250				1,250				3,750				3,750
AstraZeneca AB		MOVANTIK® and MOVANTIK® fixed-dose combination program			—				—				—				4,600
Other					104				1,997				375				5,768
License, collaboration and other revenue				$	4,875			$	131,112			$	1,082,848			$	142,028

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September 30, 2018 (in thousands):

		Nine months ended September 30, 2018
Deferred revenue—December 31, 2017		$	37,970
Transition adjustment related to adoption of ASC 606			(1,953	)
Additions to deferred revenue			4,000
Recognition of previously unearned revenue			(12,931	)
Deferred revenue—September 30, 2018		$	27,086

X

- Definition

Tabular disclosure of contract balances and changes in contract balances.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration